



## Clinical trial results:

### GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

#### Summary

EudraCT number	2018-001606-29
Trial protocol	BE GB FR SE DE PL DK ES GR FI IT
Global end of trial date	03 November 2023

#### Results information

Result version number	v2 (current)
This version publication date	09 February 2025
First version publication date	25 October 2024
Version creation reason	<ul style="list-style-type: none"><li>• Correction of full data set</li></ul> Results summary revised to align with changes made to ClinicalTrials.gov summary.

#### Trial information

##### Trial identification

Sponsor protocol code	INCB 39110-309
-----------------------	----------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Incyte Corporation
Sponsor organisation address	1801 Augustine Cutoff Drive, Wilmington, United States, 19803
Public contact	Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com
Scientific contact	Study Director, Incyte Corporation, 1 8554633463, medinfo@incyte.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 November 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 November 2023
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

Part 1 and Part 1 expansion: to identify an appropriate dose of itacitinib in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cGVHD).

Part 2: to compare the efficacy of itacitinib versus placebo in combination with corticosteroids as initial treatment for moderate or severe cGVHD.

Protection of trial subjects:

This study was to be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and conducted in adherence to the study Protocol, applicable Good Clinical Practices, and applicable laws and country-specific regulations in which the study was conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	17 January 2019
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy
Long term follow-up duration	24 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 3
Country: Number of subjects enrolled	United States: 57
Country: Number of subjects enrolled	Austria: 2
Country: Number of subjects enrolled	Belgium: 5
Country: Number of subjects enrolled	Denmark: 3
Country: Number of subjects enrolled	Germany: 27
Country: Number of subjects enrolled	Greece: 10
Country: Number of subjects enrolled	Italy: 22
Country: Number of subjects enrolled	Poland: 1
Country: Number of subjects enrolled	Spain: 20
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	Canada: 6
Country: Number of subjects enrolled	Israel: 3
Worldwide total number of subjects	160
EEA total number of subjects	90

Notes:

<b>Subjects enrolled per age group</b>	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	123
From 65 to 84 years	37
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

This study was conducted at 65 study centers in Austria, Belgium, Canada, Denmark, Germany, Greece, Israel, Italy, Poland, Spain, Switzerland, United Kingdom, and the United States.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Part 1: itacitinib 200 mg QD + CS

Arm description:

Participants were treated with oral itacitinib 200 milligrams (mg) once daily (QD) + corticosteroids (CS) for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg/day (kg) QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (chronic graft-versus-host disease [cGVHD] progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Experimental
Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

Dosage and administration details:

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Investigational medicinal product name	itacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Prolonged-release tablet
Routes of administration	Oral use

Dosage and administration details:

Two 100-mg sustained-release tablets taken orally

<b>Arm title</b>	Part 1: itacitinib 300 mg QD + CS
------------------	-----------------------------------

Arm description:

Participants were treated with oral itacitinib 300 mg QD + CS for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

Dosage and administration details:

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Investigational medicinal product name	itacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Prolonged-release tablet
Routes of administration	Oral use

Dosage and administration details:

Three 100-mg sustained-release tablets taken orally

<b>Arm title</b>	Part 1 Expansion: itacitinib 300 mg QD + CS
------------------	---

Arm description:

Participants were treated with oral itacitinib 300 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Experimental
Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

Dosage and administration details:

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Investigational medicinal product name	itacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Prolonged-release tablet
Routes of administration	Oral use

Dosage and administration details:

Three 100-mg sustained-release tablets taken orally

<b>Arm title</b>	Part 1 Expansion: itacitinib 400 mg QD + CS
------------------	---

Arm description:

Participants were treated with oral itacitinib 400 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Experimental
Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

Dosage and administration details:

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Investigational medicinal product name	itacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Prolonged-release tablet
Routes of administration	Oral use
Dosage and administration details:	
Two 100-mg sustained-release tablets taken orally	
<b>Arm title</b>	Part 1 Expansion: itacitinib 300 mg BID + CS

**Arm description:**

Participants were treated with oral itacitinib 300 mg twice daily (BID) + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). The itacitinib dose could have been decreased to 200 mg BID if a boundary was reached during safety run-in. This treatment group was discontinued due to concern of a potential increase in relapse rate. Participants in this treatment group who were ongoing were allowed to reduce to 400 mg QD plus CS. Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Experimental
Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

**Dosage and administration details:**

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Investigational medicinal product name	itacitinib
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Prolonged-release tablet
Routes of administration	Oral use

**Dosage and administration details:**

Three 100-mg sustained-release tablets taken orally

<b>Arm title</b>	Part 1 Expansion: CS monotherapy
------------------	----------------------------------

**Arm description:**

Participants were treated with CS alone. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Arm type	Active comparator
Investigational medicinal product name	corticosteroids (methylprednisolone, prednisone)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use, Intravenous use

**Dosage and administration details:**

starting dose 0.5-1.0 mg/kg per day prednisone (or methylprednisolone equivalent to prednisone dose); may have varied based on institutional practice

Number of subjects in period 1	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 300 mg QD + CS
Started	11	10	35
Completed	6	5	3
Not completed	5	5	32
Consent withdrawn by subject	2	-	2
Physician decision	-	-	4
Disease Progression; cGVHD Flare	-	-	-
Death	2	3	9
Study Terminated by Sponsor	-	2	17
Lost to follow-up	1	-	-
Discontinued Treatment and Terminated CS Tapering	-	-	-

Number of subjects in period 1	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Started	39	29	36
Completed	2	1	1
Not completed	37	28	35
Consent withdrawn by subject	4	2	3
Physician decision	3	2	3
Disease Progression; cGVHD Flare	-	-	1
Death	8	4	5
Study Terminated by Sponsor	20	20	23
Lost to follow-up	1	-	-
Discontinued Treatment and Terminated CS Tapering	1	-	-

## Baseline characteristics

### Reporting groups

Reporting group title	Part 1: itacitinib 200 mg QD + CS
Reporting group description:	
Participants were treated with oral itacitinib 200 milligrams (mg) once daily (QD) + corticosteroids (CS) for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (chronic graft-versus-host disease [cGVHD] progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1: itacitinib 300 mg QD + CS
Reporting group description:	
Participants were treated with oral itacitinib 300 mg QD + CS for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 300 mg QD + CS
Reporting group description:	
Participants were treated with oral itacitinib 300 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 400 mg QD + CS
Reporting group description:	
Participants were treated with oral itacitinib 400 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 300 mg BID + CS
Reporting group description:	
Participants were treated with oral itacitinib 300 mg twice daily (BID) + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). The itacitinib dose could have been decreased to 200 mg BID if a boundary was reached during safety run-in. This treatment group was discontinued due to concern of a potential increase in relapse rate. Participants in this treatment group who were ongoing were allowed to reduce to 400 mg QD plus CS. Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: CS monotherapy
Reporting group description:	
Participants were treated with CS alone. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	

Reporting group values	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 300 mg QD + CS
Number of subjects	11	10	35
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0



Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	9	6	28
From 65-84 years	2	4	7
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	57.2	58.4	53.6
standard deviation	± 7.07	± 15.08	± 14.01
Sex: Female, Male			
Units: participants			
Female	3	3	17
Male	8	7	18
Race, Customized			
Units: Subjects			
White/Caucasian	11	8	31
Black/African-American	0	1	2
Asian	0	1	1
Captured as "Other" in Database	0	0	1
Ethnicity, Customized			
Units: Subjects			
Hispanic or Latino	4	2	6
Not Hispanic or Latino	6	8	25
Not Reported	1	0	2
Unknown	0	0	2
Captured as "Other" in Database	0	0	0

<b>Reporting group values</b>	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Number of subjects	39	29	36
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	30	26	24
From 65-84 years	9	3	12
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	52.6	52.6	55.7
standard deviation	± 13.79	± 12.86	± 13.32
Sex: Female, Male			
Units: participants			
Female	16	14	19

Male	23	15	17
------	----	----	----

Race, Customized Units: Subjects			
White/Caucasian	36	27	34
Black/African-American	0	0	0
Asian	3	2	1
Captured as "Other" in Database	0	0	1
Ethnicity, Customized Units: Subjects			
Hispanic or Latino	8	1	5
Not Hispanic or Latino	26	19	29
Not Reported	2	4	2
Unknown	1	1	0
Captured as "Other" in Database	2	4	0

<b>Reporting group values</b>	Total		
Number of subjects	160		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	123		
From 65-84 years	37		
85 years and over	0		
Age Continuous Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units: participants			
Female	72		
Male	88		
Race, Customized Units: Subjects			
White/Caucasian	147		
Black/African-American	3		
Asian	8		
Captured as "Other" in Database	2		
Ethnicity, Customized Units: Subjects			
Hispanic or Latino	26		
Not Hispanic or Latino	113		
Not Reported	11		
Unknown	4		

Captured as "Other" in Database	6		
---------------------------------	---	--	--

## End points

### End points reporting groups

Reporting group title	Part 1: itacitinib 200 mg QD + CS
Reporting group description: Participants were treated with oral itacitinib 200 milligrams (mg) once daily (QD) + corticosteroids (CS) for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg (kg) QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (chronic graft-versus-host disease [cGVHD] progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1: itacitinib 300 mg QD + CS
Reporting group description: Participants were treated with oral itacitinib 300 mg QD + CS for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 300 mg QD + CS
Reporting group description: Participants were treated with oral itacitinib 300 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 400 mg QD + CS
Reporting group description: Participants were treated with oral itacitinib 400 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: itacitinib 300 mg BID + CS
Reporting group description: Participants were treated with oral itacitinib 300 mg twice daily (BID) + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). The itacitinib dose could have been decreased to 200 mg BID if a boundary was reached during safety run-in. This treatment group was discontinued due to concern of a potential increase in relapse rate. Participants in this treatment group who were ongoing were allowed to reduce to 400 mg QD plus CS. Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Reporting group title	Part 1 Expansion: CS monotherapy
Reporting group description: Participants were treated with CS alone. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.	
Subject analysis set title	Parts 1 and 1 Expansion; PK Analysis: 100 mg QD + CS
Subject analysis set type	Full analysis
Subject analysis set description: For toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors, participants who received a starting dose of itacitinib 200 mg or 300 mg QD + CS in Part 1 and a starting dose of itacitinib 300 mg or 400 mg QD + CS in Part 1 Expansion had first or second dose reductions to itacitinib 100 mg QD + CS and/or dose interruptions.	
Subject analysis set title	Parts 1 and 1 Expansion; PK Analysis: itacitinib 200 mg QD+CS
Subject analysis set type	Full analysis
Subject analysis set description: Participants were treated with a starting dose of oral itacitinib 200 mg QD + CS in Part 1 or had a dose reduction to oral itacitinib 200 mg QD + CS in Part 1 or Part 1 Expansion. CS were given at a starting	

dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). For toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors, participants who received a starting dose of itacitinib 300 mg QD + CS in Part 1 and a starting dose of itacitinib 300 mg or 400 mg QD + CS in Part 1 Expansion had first or second dose reductions to itacitinib 200 mg QD + CS and/or dose interruptions.

Subject analysis set title	Parts 1 and 1 Expansion; PK Analysis: itacitinib 300 mg QD+CS
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were treated with a starting dose of oral itacitinib 300 mg QD + CS in Part 1 or Part 1 Expansion or had a dose reduction to oral itacitinib 300 mg QC + CS in Part 1 Expansion. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (chronic graft-versus-host disease [cGVHD] progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months. For toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors, participants who received a starting dose of itacitinib 400 mg QD + CS in Part 1 Expansion had a dose reduction to itacitinib 300 mg QD + CS and/or dose interruptions.

Subject analysis set title	Part 1 Expansion; PK Analysis: itacitinib 400 mg QD + CS
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were treated with oral itacitinib 400 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months. This group also included participants who originally received itacitinib 300 mg BID + CS but were ongoing at the time the 300 mg BID + CS treatment group was discontinued due to concern of a potential increase in relapse rate. At the time of discontinuation of the itacitinib 300 mg BID + CS treatment arm, participants reduced to itacitinib 400 mg QD + CS.

Subject analysis set title	Part 1 Expansion; PK Analysis: itacitinib 100 mg BID + CS
Subject analysis set type	Full analysis

Subject analysis set description:

For toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors, participants who received a starting dose of itacitinib 300 mg BID + CS in Part 1 Expansion had first or second dose reductions to itacitinib 100 mg BID + CS and/or dose interruptions.

Subject analysis set title	Part 1 Expansion; PK Analysis: itacitinib 200 mg BID + CS
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were treated with a starting dose of oral itacitinib 300 mg BID + CS in Part 1 Expansion and had their dose decreased to itacitinib 200 mg BID + CS because a boundary was reached during safety run-in or for toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months. For toxicity management purposes and/or due to coadministration of strong CYP3A4 inhibitors, participants who received a starting dose of itacitinib 300 mg BID + CS in Part 1 Expansion had a dose reduction to itacitinib 200 mg BID + CS and/or dose interruptions.

Subject analysis set title	Part 1 Expansion; PK Analysis: itacitinib 300 mg BID + CS
Subject analysis set type	Full analysis

Subject analysis set description:

Participants were treated with oral itacitinib 300 mg BID + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). The itacitinib dose could have been decreased to 200 mg BID if a boundary was reached during safety run-in. This treatment group was discontinued due to concern of a potential increase in relapse rate. Participants in this treatment group who were ongoing were allowed to reduce to 400 mg QD + CS. Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

---

**Primary: Part 1 Expansion: Number of participants with any treatment-emergent adverse event (TEAE)**

---

End point title	Part 1 Expansion: Number of participants with any treatment-emergent adverse event (TEAE) <sup>[1][2]</sup>
-----------------	---

End point description:

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE either reported for the first time or the worsening of a pre-existing event after the first dose of study drug.

End point type	Primary
----------------	---------

End point timeframe:

until at least 30 days after the last dose of study treatment (up to 1103 days)

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: participants	34	38	28	32

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Part 1: Number of participants with dose-limiting toxicities (DLTs)**

---

End point title	Part 1: Number of participants with dose-limiting toxicities (DLTs) <sup>[3][4]</sup>
-----------------	---

End point description:

A DLT was defined as the occurrence of any protocol-defined toxicity with onset up to and including Day 28, except those with a clear alternative explanation. Participants who received at least 21 of 28 doses of study drug at the level assigned or had a DLT were considered evaluable for determining tolerability of the dose. Participants who did not achieve this duration of exposure and did not have a DLT were to be replaced for purposes of toxicity identification.

End point type	Primary
----------------	---------

End point timeframe:

up to Day 28

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical analysis was not conducted for this endpoint.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: participants	0	1		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1 Expansion: Response rate at Months 3 and 6

End point title	Part 1 Expansion: Response rate at Months 3 and 6 <sup>[5]</sup>
-----------------	--

End point description:

Response rate was defined as the percentage of participants that had CR or PR, per NIH Consensus Criteria, as determined by the investigator, within 14 days of the post-Baseline visit date until new anti-GVHD therapy or overall response-progression or relapse/progression of underlying disease. CR was defined as the complete resolution of all signs and symptoms of cGvHD in all evaluable organs. PR was defined as an improvement in at least one organ without progression in other organs.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 3 and 6

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: percentage of participants				
number (confidence interval 95%)				
Month 3	60.0 (42.1 to 76.1)	69.2 (52.4 to 83.0)	58.6 (38.9 to 76.5)	50.0 (32.9 to 67.1)
Month 6	42.9 (26.3 to 60.6)	53.8 (37.2 to 69.9)	34.5 (17.9 to 54.3)	36.1 (20.8 to 53.8)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 1 Expansion: Cmax of itacitinib

End point title	Parts 1 and 1 Expansion: Cmax of itacitinib
-----------------	---

End point description:

Cmax was defined as the maximum observed concentration of itacitinib. 9999=SD cannot be reported for a single participant. 8888=Analysis was not conducted at this time point. Pharmacokinetic (PK) Evaluable Population: all participants who received at least 1 dose of study drug and/or reference therapy and provided at least 1 corresponding post-dose plasma sample (1 PK measurement). Because

Part I and Part I Expansion were both randomized, open label, and had a parallel design with the same participant population criteria, as pre-specified, the PK data for identical doses/frequency of dosing were grouped for analysis (rather than conducting analysis by treatment arm).

End point type	Secondary
End point timeframe:	
Days 1, 7, and 28: predose and 1, 2, and 5 hours post-dose	

End point values	Parts 1 and 1 Expansion; PK Analysis: 100 mg QD + CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 200 mg QD+CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 300 mg QD+CS	Part 1 Expansion; PK Analysis: itacitinib 400 mg QD + CS
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3 <sup>[6]</sup>	27 <sup>[7]</sup>	35 <sup>[8]</sup>	26 <sup>[9]</sup>
Units: nanomoles per Liter (nmol/L)				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	201 (± 9999)	655 (± 82.9)	1050 (± 87.3)	951 (± 68.0)
Day 7, n=1, 27, 32, 26, 0 14, 12	191 (± 9999)	1070 (± 88.9)	1580 (± 125)	1190 (± 103)
Day 28, n=3, 26, 27, 21, 3, 8, 10	486 (± 140)	1460 (± 67.3)	1290 (± 248)	1350 (± 72.2)

Notes:

[6] - PK Evaluable Population

[7] - PK Evaluable Population

[8] - PK Evaluable Population

[9] - PK Evaluable Population

End point values	Part 1 Expansion; PK Analysis: itacitinib 100 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 200 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 300 mg BID + CS	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	3 <sup>[10]</sup>	14 <sup>[11]</sup>	16 <sup>[12]</sup>	
Units: nanomoles per Liter (nmol/L)				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (± 8888)	769 (± 118)	736 (± 79.1)	
Day 7, n=1, 27, 32, 26, 0 14, 12	8888 (± 8888)	1520 (± 73.0)	1110 (± 66.2)	
Day 28, n=3, 26, 27, 21, 3, 8, 10	1350 (± 29.4)	2040 (± 62.6)	1580 (± 51.4)	

Notes:

[10] - PK Evaluable Population

[11] - PK Evaluable Population

[12] - PK Evaluable Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Parts 1 and 1 Expansion: Ctau (trough concentration of itacitinib over the dose interval) of itacitinib

End point title	Parts 1 and 1 Expansion: Ctau (trough concentration of itacitinib over the dose interval) of itacitinib
-----------------	---



**End point description:**

9999=SD cannot be reported for a single participant. 8888=The absence of terminal PK measurements at baseline visits for the timepoint beyond 6 hours did not allow for precise and reasonable NCA estimates (as more than 3 PK data points are necessary beyond C<sub>max</sub>). 7777=The absence of terminal PK measurements at baseline visits for the timepoint beyond 6 hours did not allow for precise and reasonable NCA estimates (as more than 3 PK data points are necessary beyond C<sub>max</sub>). Of the total participants analyzed, only 1 participant had a PK profile that allowed for the NCA estimate of the parameter. The calculation of the SD was not possible. Because Part I and Part I Expansion were both randomized, open label, and had a parallel design with the same participant population criteria, as pre-specified, the PK data for identical doses/frequency of dosing were grouped for analysis (rather than conducting analysis by treatment arm).

End point type	Secondary
----------------	-----------

**End point timeframe:**

Day 1: predose, and 1, 2, and 5 hours post-dose. Days 7 and 28: predose, and 1, 2, 5, 12 (for BID dosing), and 24 hours post-dose (for QD dosing)

End point values	Parts 1 and 1 Expansion; PK Analysis: 100 mg QD + CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 200 mg QD+CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 300 mg QD+CS	Part 1 Expansion; PK Analysis: itacitinib 400 mg QD + CS
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3 <sup>[13]</sup>	27 <sup>[14]</sup>	35 <sup>[15]</sup>	26 <sup>[16]</sup>
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (± 8888)	8888 (± 8888)	0.153 (± 7777)	135 (± 197)
Day 7, n=1, 27, 31, 24, 0, 14, 12	0.298 (± 9999)	53.6 (± 218)	52.2 (± 425)	33.5 (± 118)
Day 28, n=3, 26, 26, 20, 3, 8, 10	10.4 (± 4440)	68.0 (± 314)	42.2 (± 182)	29.7 (± 152)

**Notes:**

[13] - PK Evaluable Population

[14] - PK Evaluable Population

[15] - PK Evaluable Population

[16] - PK Evaluable Population

End point values	Part 1 Expansion; PK Analysis: itacitinib 100 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 200 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 300 mg BID + CS	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	3 <sup>[17]</sup>	14 <sup>[18]</sup>	16 <sup>[19]</sup>	
Units: nmol/L				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (± 8888)	7.54 (± 7777)	8888 (± 8888)	
Day 7, n=1, 27, 31, 24, 0, 14, 12	8888 (± 8888)	483 (± 175)	127 (± 177)	
Day 28, n=3, 26, 26, 20, 3, 8, 10	392 (± 85.6)	460 (± 123)	195 (± 116)	

**Notes:**

[17] - PK Evaluable Population

[18] - PK Evaluable Population

[19] - PK Evaluable Population

**Statistical analyses**

**Secondary: Parts 1 and 1 Expansion: tmax (time to the maximum concentration of itacitinib) of itacitinib**

End point title	Parts 1 and 1 Expansion: tmax (time to the maximum concentration of itacitinib) of itacitinib
End point description:	
8888=Analysis was not conducted at this time point. Because Part I and Part I Expansion were both randomized, open label, and had a parallel design with the same participant population criteria, as pre-specified, the PK data for identical doses/frequency of dosing were grouped for analysis (rather than conducting analysis by treatment arm). For pharmacokinetic steady state Day 7 and Day 28, for the calculation of noncompartmental analysis exposure estimates (as more than 3 PK data points are necessary for the estimation beyond Cmax) it was assumed, that PK concentration returns to the predose value (at 12 hours post-dose for BID dosing; at 24 hours post-dose for QD dosing). Predose PK samples were transposed to 24 hours post-dose for QD administration and to 12 hours post-dose for BID administration to allow the steady-state NCA PK estimates on Day 7 and Day 28.	
End point type	Secondary
End point timeframe:	
Day 1: predose, and 1, 2, and 5 hours post-dose. Days 7 and 28: predose, and 1, 2, 5, 12 (for BID dosing), and 24 hours post-dose (for QD dosing)	

End point values	Parts 1 and 1 Expansion; PK Analysis: 100 mg QD + CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 200 mg QD+CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 300 mg QD+CS	Part 1 Expansion; PK Analysis: itacitinib 400 mg QD + CS
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3 <sup>[20]</sup>	27 <sup>[21]</sup>	35 <sup>[22]</sup>	26 <sup>[23]</sup>
Units: hours				
median (full range (min-max))				
Day 1, n=1, 23, 35, 26, 0, 12, 16	1.0 (1.0 to 1.0)	2.1 (0.9 to 4.8)	2.1 (0.8 to 5.0)	2.0 (0.0 to 5.0)
Day 7, n=1, 27, 32, 26, 0, 14, 12	1.0 (1.0 to 1.0)	2.1 (0.0 to 5.0)	2.0 (1.0 to 13.4)	2.0 (1.0 to 5.2)
Day 28, n=3, 26, 27, 21, 3, 8, 10	4.0 (1.0 to 4.8)	3.1 (0.8 to 12.0)	2.0 (0.0 to 16.9)	2.1 (0.9 to 5.0)

Notes:

[20] - PK Evaluable Population

[21] - PK Evaluable Population

[22] - PK Evaluable Population

[23] - PK Evaluable Population

End point values	Part 1 Expansion; PK Analysis: itacitinib 100 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 200 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 300 mg BID + CS	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	3 <sup>[24]</sup>	14 <sup>[25]</sup>	16 <sup>[26]</sup>	
Units: hours				
median (full range (min-max))				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (8888 to 8888)	2.0 (1.0 to 5.0)	2.4 (1.0 to 5.0)	
Day 7, n=1, 27, 32, 26, 0, 14, 12	8888 (8888 to 8888)	1.9 (0.0 to 10.7)	2.0 (0.9 to 5.0)	
Day 28, n=3, 26, 27, 21, 3, 8, 10	2.0 (2.0 to 2.2)	2.3 (2.0 to 5.6)	2.0 (1.0 to 5.0)	

Notes:

[24] - PK Evaluable Population

[25] - PK Evaluable Population

[26] - PK Evaluable Population

## Statistical analyses

No statistical analyses for this end point

### Secondary: Parts 1 and 1 Expansion: Cl/F (apparent oral dose clearance of itacitinib) of itacitinib

End point title	Parts 1 and 1 Expansion: Cl/F (apparent oral dose clearance of itacitinib) of itacitinib
-----------------	--

End point description:

9999=SD cannot be reported for a single participant. 8888=The absence of terminal PK measurements at baseline visits for the timepoint beyond 6 hours did not allow for precise and reasonable NCA estimates (as more than 3 PK data points are necessary beyond C<sub>max</sub>). 7777=The absence of terminal PK measurements at baseline visits for the timepoint beyond 6 hours did not allow for precise and reasonable NCA estimates (as more than 3 PK data points are necessary beyond C<sub>max</sub>). Of the total participants analyzed, only 1 participant had a PK profile that allowed for the noncompartmental analysis estimate of the parameter. The calculation of the SD was not possible. Because Part I and Part I Expansion were both randomized, open label, and had a parallel design with the same participant population criteria, as pre-specified, the PK data for identical doses/frequency of dosing were grouped for analysis (rather than conducting analysis by treatment arm).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1: predose, and 1, 2, and 5 hours post-dose. Days 7 and 28: predose, and 1, 2, 5, 12 (for BID dosing), and 24 hours post-dose (for QD dosing)

End point values	Parts 1 and 1 Expansion; PK Analysis: 100 mg QD + CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 200 mg QD+CS	Parts 1 and 1 Expansion; PK Analysis: itacitinib 300 mg QD+CS	Part 1 Expansion; PK Analysis: itacitinib 400 mg QD + CS
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	Subject analysis set
Number of subjects analysed	3 <sup>[27]</sup>	27 <sup>[28]</sup>	35 <sup>[29]</sup>	26 <sup>[30]</sup>
Units: Liters per hour				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (± 8888)	8888 (± 8888)	258 (± 7777)	41.2 (± 130)
Day 7, n=1, 27, 31, 24, 0, 14, 12	224 (± 9999)	43.0 (± 105)	48.9 (± 159)	85.9 (± 90.7)
Day 28, n=3, 26, 26, 20, 3, 8, 10	47.7 (± 211)	30.0 (± 96.9)	54.8 (± 189)	81.0 (± 65.1)

Notes:

[27] - PK Evaluable Population

[28] - PK Evaluable Population

[29] - PK Evaluable Population

[30] - PK Evaluable Population

End point values	Part 1 Expansion; PK Analysis: itacitinib 100 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 200 mg BID + CS	Part 1 Expansion; PK Analysis: itacitinib 300 mg BID + CS	
------------------	---	---	---	--

Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	3 <sup>[31]</sup>	14 <sup>[32]</sup>	16 <sup>[33]</sup>	
Units: Liters per hour				
geometric mean (geometric coefficient of variation)				
Day 1, n=1, 23, 35, 26, 0, 12, 16	8888 (± 8888)	640 (± 7777)	8888 (± 8888)	
Day 7, n=1, 27, 31, 24, 0, 14, 12	8888 (± 8888)	31.8 (± 82.9)	94.4 (± 61.3)	
Day 28, n=3, 26, 26, 20, 3, 8, 10	20.2 (± 54.2)	26.9 (± 75.5)	67.5 (± 62.1)	

Notes:

[31] - PK Evaluable Population

[32] - PK Evaluable Population

[33] - PK Evaluable Population

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1: Response rate at Months 3, 6, and 12

End point title	Part 1: Response rate at Months 3, 6, and 12 <sup>[34]</sup>
-----------------	--

End point description:

Response rate was defined as the percentage of participants that had CR or PR, per NIH Consensus Criteria, as determined by the investigator, within 14 days of the post-Baseline visit date until new anti-GVHD therapy or overall response-progression or relapse/progression of underlying disease. CR was defined as the complete resolution of all signs and symptoms of cGvHD in all evaluable organs. PR was defined as an improvement in at least one organ without progression in other organs.

End point type	Secondary
----------------	-----------

End point timeframe:

Months 3, 6, and 12

Notes:

[34] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	11	10		
Units: percentage of participants				
number (confidence interval 95%)				
Month 3	63.6 (30.8 to 89.1)	50.0 (18.7 to 81.3)		
Month 6	36.4 (10.9 to 69.2)	50.0 (18.7 to 81.3)		
Month 12	18.2 (2.3 to 51.8)	20.0 (2.5 to 55.6)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1 Expansion: Response rate at Month 12

End point title	Part 1 Expansion: Response rate at Month 12 <sup>[35]</sup>
End point description:	
Response rate was defined as the percentage of participants that had CR or PR, per NIH Consensus Criteria, as determined by the investigator, within 14 days of the post-Baseline visit date until new anti-GVHD therapy or overall response-progression or relapse/progression of underlying disease. CR was defined as the complete resolution of all signs and symptoms of cGvHD in all evaluable organs. PR was defined as an improvement in at least one organ without progression in other organs.	
End point type	Secondary
End point timeframe:	
Month 12	
Notes:	
[35] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Statistical analysis was not conducted for this endpoint.	

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: percentage of participants				
number (confidence interval 95%)	22.9 (10.4 to 40.1)	41.0 (25.6 to 57.9)	24.1 (10.3 to 43.5)	19.4 (8.2 to 36.0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1 Expansion: Overall survival

End point title	Part 1 Expansion: Overall survival <sup>[36]</sup>
End point description:	
Overall survival was defined as the interval between the date of randomization and the date of death due to any cause. -9999, 9999=the median and the upper and lower limits of the confidence interval were not estimable because too few participants died.	
End point type	Secondary
End point timeframe:	
up to 36 months	
Notes:	
[36] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.	
Justification: Statistical analysis was not conducted for this endpoint.	

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: days				
median (confidence interval 95%)	9999 (694.0 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Duration of response

End point title	Part 1 Expansion: Duration of response <sup>[37]</sup>
-----------------	--

End point description:

Duration to response was defined as the interval between the first response and cGVHD progression, death, or the initiation of a new systemic cGVHD therapy. 9999=the median and the upper limit of the confidence interval were not estimable because too few participants had disease progression or died or initiated new systemic cGVHD therapy.

End point type	Secondary
----------------	-----------

End point timeframe:

up to 24 months

Notes:

[37] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	31	25	26
Units: days				
median (confidence interval 95%)	581.0 (147.0 to 807.0)	9999 (306.0 to 9999)	512.0 (161.0 to 9999)	197.0 (103.0 to 9999)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Time to response

End point title	Part 1 Expansion: Time to response <sup>[38]</sup>
-----------------	--

End point description:

Time to response was defined as the interval between randomization and the first response (CR or PR) before initiation of new therapy. CR was defined as the complete resolution of all signs and symptoms of cGVHD in all evaluable organs. PR was defined as an improvement in at least one organ without progression in other organs.

End point type	Secondary
----------------	-----------

End point timeframe:

up to Month 12

Notes:

[38] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	31	31	25	26
Units: days				
median (full range (min-max))	16.0 (12 to 120)	16.0 (12 to 86)	16.0 (13 to 145)	16.0 (13 to 88)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Percentage of participants successfully tapered off all corticosteroids at Day 180

End point title	Part 1 Expansion: Percentage of participants successfully tapered off all corticosteroids at Day 180 <sup>[39]</sup>
End point description:	The percentage of participants who were not taking any corticosteroids at Day 180 was assessed.
End point type	Secondary
End point timeframe:	Day 180

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	27	17	18
Units: percentage of participants				
number (not applicable)	52.4	66.7	47.1	44.4

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Percentage of participants with a ≥50% reduction in daily corticosteroid dose at Day 180 from the corticosteroid dose on Day 1

End point title	Part 1 Expansion: Percentage of participants with a ≥50%
-----------------	--

reduction in daily corticosteroid dose at Day 180 from the corticosteroid dose on Day 1<sup>[40]</sup>

End point description:

The corticosteroid dose at Day 180 was compared to the corticosteroid dose on Day 1 to assess reduction.

End point type Secondary

End point timeframe:

Day 1; Day 180

Notes:

[40] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	21	27	17	18
Units: percentage of participants				
number (not applicable)	90.5	100.0	100.0	100.0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Part 1 Expansion: Nonrelapse mortality (NRM) rate

End point title Part 1 Expansion: Nonrelapse mortality (NRM) rate<sup>[41]</sup>

End point description:

NRM was defined as the percentage of participants who died due to causes other than a relapse of their primary hematologic disease.

End point type Secondary

End point timeframe:

up to 24 months

Notes:

[41] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	37	28	35
Units: percentage of participants				
number (confidence interval 95%)	25.7 (12.5 to 43.3)	15.4 (6.2 to 32.0)	10.3 (2.3 to 28.2)	11.1 (3.2 to 26.7)



## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Relapse rate of malignant and nonmalignant hematologic diseases

End point title	Part 1 Expansion: Relapse rate of malignant and nonmalignant hematologic diseases <sup>[42]</sup>
-----------------	---

End point description:

The relapse rate was defined as percentage of participants whose underlying disease relapsed at any time during the course of the study.

End point type	Secondary
----------------	-----------

End point timeframe:

up to 1073 days

Notes:

[42] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

End point values	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: percentage of participants				
number (confidence interval 95%)	5.7 (0.7 to 19.2)	7.7 (1.6 to 20.9)	13.8 (3.9 to 31.7)	2.8 (0.1 to 14.5)

## Statistical analyses

No statistical analyses for this end point

### Secondary: Part 1 Expansion: Time to primary hematologic disease relapse

End point title	Part 1 Expansion: Time to primary hematologic disease
-----------------	---

End point description:

Time to primary hematologic disease relapse was defined as the interval between the date of randomization and the date of relapse. -9999, 9999=Too few participants had an event of relapse for a meaningful median/95% confidence interval to be calculated; thus, the Kaplan-Meier estimator cannot provide a valid estimate. Analysis included censored participants. Censored participants didn't have an event of relapse at any time up to the last assessment date. Participants who didn't have an event of hematologic disease relapse were censored at the time of the last assessment.

End point type	Secondary
----------------	-----------

End point timeframe:

up to 24 months

Notes:

[43] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: Statistical analysis was not conducted for this endpoint.

<b>End point values</b>	Part 1 Expansion: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: CS monotherapy
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	35	39	29	36
Units: days				
median (confidence interval 95%)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)	9999 (-9999 to 9999)

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

until at least 30 days after the last dose of study treatment (up to 1103 days)

Adverse event reporting additional description:

TEAEs have been reported. As pre-specified in the SAP, the overall summary of AEs by treatment group included the number of participants with itacitinib dose reductions due to AEs or concomitant strong CYP3A4 inhibitors. The SAP defines "treatment groups" as those to which participants were originally randomized.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22
--------------------	----

### Reporting groups

Reporting group title	Part 1: itacitinib 200 mg QD + CS
-----------------------	-----------------------------------

Reporting group description:

Participants were treated with oral itacitinib 200 milligrams (mg) once daily (QD) + corticosteroids (CS) for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kilogram (kg) QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (chronic graft-versus-host disease [cGVHD] progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Reporting group title	Part 1: itacitinib 300 mg QD + CS
-----------------------	-----------------------------------

Reporting group description:

Participants were treated with oral itacitinib 300 mg QD + CS for a maximum of 36 months. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Reporting group title	Part 1 Expansion: itacitinib 300 mg QD + CS
-----------------------	---

Reporting group description:

Participants were treated with oral itacitinib 300 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Reporting group title	Part 1 Expansion: itacitinib 400 mg QD + CS
-----------------------	---

Reporting group description:

Participants were treated with oral itacitinib 400 mg QD + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Reporting group title	Part 1 Expansion: itacitinib 300 mg BID + CS
-----------------------	--

Reporting group description:

Participants were treated with oral itacitinib 300 mg twice daily (BID) + CS. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). The itacitinib dose could have been decreased to 200 mg BID if a boundary was reached during safety run-in. This treatment group was discontinued due to concern of a potential increase in relapse rate. Participants in this treatment group who were ongoing were allowed to reduce to 400 mg QD plus CS. Itacitinib treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

Reporting group title	Part 1 Expansion: Total
-----------------------	-------------------------

Reporting group description:

Participants received 300 mg QD, 400 mg QD, or 300 mg BID itacitinib plus corticosteroids.

Reporting group title	Part 1 Expansion: CS monotherapy
-----------------------	----------------------------------

Reporting group description:

Participants were treated with CS alone. CS were given at a starting dose of 0.5 to 1.0 mg/kg QD (prednisone or methylprednisolone equivalent to prednisone dose). Treatment was to continue until treatment failure (cGVHD progression, death, or initiation of new systemic cGVHD therapy), unacceptable toxicity, or withdrawal of consent, for a maximum of 36 months.

<b>Serious adverse events</b>	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 300 mg QD + CS
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 11 (54.55%)	5 / 10 (50.00%)	18 / 35 (51.43%)
number of deaths (all causes)	2	3	9
number of deaths resulting from adverse events	1	1	3
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Small cell lung cancer			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic limb pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venoocclusive disease			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site inflammation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Physical deconditioning			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	1 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Bronchiolitis obliterans syndrome			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Psychiatric decompensation subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactic acid increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
SARS-CoV-2 test positive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lumbar vertebral fracture			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Bundle branch block left			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0



Myocardial infarction			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Epilepsy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic neuritis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness unilateral			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Hepatic fibrosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver injury			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Night sweats			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Cystitis haemorrhagic			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Dysuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pollakiuria			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Bronchopulmonary aspergillosis subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19 pneumonia subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridial sepsis subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection reactivation subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis viral subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus oesophagitis			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Escherichia coli			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster cutaneous disseminated			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences causally related to treatment / all	1 / 2	0 / 1	1 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia parainfluenzae viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia cytomegaloviral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia streptococcal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Respiratory syncytial virus infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Streptococcal sepsis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			



subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection viral			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food intolerance			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1 Expansion:	Part 1 Expansion:	Part 1 Expansion:
-------------------------------	-------------------	-------------------	-------------------

	itacitinib 400 mg QD + CS	itacitinib 300 mg BID + CS	Total
Total subjects affected by serious adverse events			
subjects affected / exposed	22 / 39 (56.41%)	12 / 29 (41.38%)	52 / 103 (50.49%)
number of deaths (all causes)	8	4	21
number of deaths resulting from adverse events	4	1	8
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Small cell lung cancer			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ischaemic limb pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Venoocclusive disease			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chills			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Catheter site inflammation			

subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaise			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oedema peripheral			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Physical deconditioning			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	4 / 39 (10.26%)	0 / 29 (0.00%)	4 / 103 (3.88%)
occurrences causally related to treatment / all	2 / 4	0 / 0	2 / 4
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sudden death			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Aspiration			

subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchiolitis obliterans syndrome			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Psychiatric disorders			
Confusional state			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Mental status changes			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric decompensation			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			

Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	1 / 1	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood bilirubin increased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood lactic acid increased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
International normalised ratio increased			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Platelet count decreased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

SARS-CoV-2 test positive subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Lumbar vertebral fracture subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haematoma subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thoracic vertebral fracture subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Bundle branch block left subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac failure subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myocardial infarction subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Cerebral haemorrhage			

subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Epilepsy			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Optic neuritis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Syncope			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Blindness unilateral			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Retinal vein occlusion			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences causally related to treatment / all	1 / 1	0 / 0	3 / 5
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Anal haemorrhage			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal pain upper			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Colitis			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 1	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diarrhoea			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lower gastrointestinal haemorrhage			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	1 / 1	1 / 1	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Oesophagitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			



subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	2 / 2	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Hepatobiliary disorders</b>			
Hepatic fibrosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Liver injury			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Skin and subcutaneous tissue disorders</b>			
Erythema			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Night sweats			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
<b>Renal and urinary disorders</b>			
Cystitis haemorrhagic			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dysuria			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haematuria			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pollakiuria			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myalgia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Myositis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Osteonecrosis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
COVID-19			
subjects affected / exposed	3 / 39 (7.69%)	2 / 29 (6.90%)	6 / 103 (5.83%)
occurrences causally related to treatment / all	0 / 3	0 / 2	1 / 6
deaths causally related to treatment / all	0 / 1	0 / 1	0 / 2

COVID-19 pneumonia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridial sepsis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Clostridium difficile colitis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection reactivation			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cystitis viral			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cytomegalovirus oesophagitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Diverticulitis			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			

subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis salmonella			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis Escherichia coli			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Herpes zoster cutaneous disseminated			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neutropenic sepsis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peritonitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Parainfluenzae virus infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	5 / 39 (12.82%)	2 / 29 (6.90%)	9 / 103 (8.74%)
occurrences causally related to treatment / all	2 / 5	1 / 2	4 / 10
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 1
Pneumonia parainfluenzae viral			

subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia fungal			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Pneumonia cytomegaloviral			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences causally related to treatment / all	2 / 2	0 / 0	3 / 3
deaths causally related to treatment / all	1 / 1	0 / 0	1 / 1
Pneumonia streptococcal			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Progressive multifocal leukoencephalopathy			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pseudomonal sepsis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	1 / 1
Respiratory syncytial virus infection			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	3 / 103 (2.91%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Salmonella sepsis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			

subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sinusitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Staphylococcal sepsis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Streptococcal sepsis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Systemic infection			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Upper respiratory tract infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	2 / 103 (1.94%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection viral			

subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	1 / 1	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Failure to thrive			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	1 / 1	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Food intolerance			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypokalaemia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Part 1 Expansion: CS monotherapy		
Total subjects affected by serious adverse events			
subjects affected / exposed	9 / 36 (25.00%)		
number of deaths (all causes)	5		
number of deaths resulting from adverse events	1		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Small cell lung cancer			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Hypotension			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ischaemic limb pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Venoocclusive disease			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Chills			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Catheter site inflammation			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		



Malaise				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oedema				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oedema peripheral				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Physical deconditioning				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyrexia				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Sudden death				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Aspiration				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Bronchiolitis obliterans syndrome				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			

Dyspnoea			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypoxia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Confusional state			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Mental status changes			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric decompensation			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alanine aminotransferase increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Aspartate aminotransferase increased				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood bilirubin increased				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Blood lactic acid increased				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Gamma-glutamyltransferase increased				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
International normalised ratio increased				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Platelet count decreased				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
SARS-CoV-2 test positive				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 1			
Injury, poisoning and procedural complications				
Lumbar vertebral fracture				

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haematoma			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thoracic vertebral fracture			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Bundle branch block left			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac failure			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Myocardial infarction			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Cerebral haemorrhage			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Epilepsy			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Optic neuritis			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Syncope			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Eye disorders			
Blindness unilateral			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Retinal vein occlusion			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Anal haemorrhage			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Abdominal pain upper				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Colitis				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	0 / 1			
deaths causally related to treatment / all	0 / 0			
Diarrhoea				
subjects affected / exposed	2 / 36 (5.56%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 0			
Lower gastrointestinal haemorrhage				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Oesophagitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pancreatitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Vomiting				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hepatobiliary disorders				
Hepatic fibrosis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Liver injury				

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Skin and subcutaneous tissue disorders			
Erythema			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Night sweats			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Cystitis haemorrhagic			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Dysuria			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Haematuria			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pollakiuria			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Muscular weakness			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Myalgia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Myositis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Osteonecrosis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bronchopulmonary aspergillosis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
COVID-19			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
COVID-19 pneumonia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridial sepsis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Clostridium difficile colitis			



subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus infection reactivation				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus infection				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cystitis viral				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Cytomegalovirus oesophagitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Diverticulitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Escherichia bacteraemia				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis salmonella				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Gastroenteritis Escherichia coli				

subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Herpes zoster cutaneous disseminated				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Neutropenic sepsis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Peritonitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Parainfluenzae virus infection				
subjects affected / exposed	1 / 36 (2.78%)			
occurrences causally related to treatment / all	1 / 1			
deaths causally related to treatment / all	0 / 0			
Pneumonia				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia parainfluenzae viral				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia fungal				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia cytomegaloviral				

subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pneumonia streptococcal				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Progressive multifocal leukoencephalopathy				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pseudomonal sepsis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory syncytial virus infection				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Salmonella sepsis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sepsis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Sinusitis				
subjects affected / exposed	0 / 36 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Staphylococcal sepsis				

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Streptococcal sepsis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Systemic infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Upper respiratory tract infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Urinary tract infection viral			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Dehydration			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Failure to thrive			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Food intolerance			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Hypokalaemia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Part 1: itacitinib 200 mg QD + CS	Part 1: itacitinib 300 mg QD + CS	Part 1 Expansion: itacitinib 300 mg QD + CS
Total subjects affected by non-serious adverse events			
subjects affected / exposed	11 / 11 (100.00%)	10 / 10 (100.00%)	33 / 35 (94.29%)
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	2 / 11 (18.18%)	2 / 10 (20.00%)	6 / 35 (17.14%)
occurrences (all)	2	3	6
Hypotension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	0	0	3

Microangiopathy subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	4 / 35 (11.43%) 5
Chest discomfort subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	2 / 35 (5.71%) 2
Fatigue subjects affected / exposed occurrences (all)	4 / 11 (36.36%) 4	2 / 10 (20.00%) 3	6 / 35 (17.14%) 7
Influenza like illness subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Oedema subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	1 / 10 (10.00%) 1	1 / 35 (2.86%) 1
Oedema peripheral subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	0 / 10 (0.00%) 0	6 / 35 (17.14%) 6
Pyrexia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 2	1 / 10 (10.00%) 1	4 / 35 (11.43%) 6
Immune system disorders			
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	1 / 35 (2.86%) 1
Reproductive system and breast disorders			
Breast pain subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	1 / 35 (2.86%) 1
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0

Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	1 / 35 (2.86%) 1
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Dyspnoea subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	1 / 10 (10.00%) 1	5 / 35 (14.29%) 7
Epistaxis subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 10 (10.00%) 1	2 / 35 (5.71%) 2
Productive cough subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	2 / 35 (5.71%) 2
Pulmonary oedema subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	2 / 35 (5.71%) 2
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	1 / 35 (2.86%) 1
Confusional state subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	0 / 35 (0.00%) 0
Depression			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	3 / 35 (8.57%)
occurrences (all)	1	1	3
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	5 / 35 (14.29%)
occurrences (all)	0	2	7
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	5	0	5
Blood phosphorus decreased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	3	1	1
Blood bilirubin increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Blood cholesterol increased			
subjects affected / exposed	3 / 11 (27.27%)	2 / 10 (20.00%)	3 / 35 (8.57%)
occurrences (all)	3	2	3
Blood creatinine increased			
subjects affected / exposed	3 / 11 (27.27%)	2 / 10 (20.00%)	3 / 35 (8.57%)
occurrences (all)	6	2	3
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Blood potassium decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			



subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	1	1	1
Blood sodium decreased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	2	1	1
Blood triglycerides increased			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	2	1	1
Cytomegalovirus test positive			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Drug level increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Haemoglobin decreased			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	3 / 35 (8.57%)
occurrences (all)	0	2	3
Haemoglobin increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Liver function test increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Platelet count decreased			
subjects affected / exposed	5 / 11 (45.45%)	3 / 10 (30.00%)	6 / 35 (17.14%)
occurrences (all)	5	3	6

Weight increased subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	1 / 35 (2.86%) 1
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	2 / 35 (5.71%) 2
Fall subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	1 / 10 (10.00%) 1	1 / 35 (2.86%) 3
Limb injury subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	2 / 35 (5.71%) 2
Cardiac disorders			
Atrial fibrillation subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	3 / 35 (8.57%) 3
Bradycardia subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Cardiac failure subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	4 / 35 (11.43%) 5
Nervous system disorders			
Balance disorder subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0

Dizziness			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	3 / 35 (8.57%)
occurrences (all)	0	1	3
Dysgeusia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Headache			
subjects affected / exposed	2 / 11 (18.18%)	2 / 10 (20.00%)	2 / 35 (5.71%)
occurrences (all)	2	2	2
Hypoaesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	0	1	2
Paraesthesia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Sciatica			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Presyncope			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Polyneuropathy			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	2
Tremor			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 11 (27.27%)	2 / 10 (20.00%)	14 / 35 (40.00%)
occurrences (all)	4	2	18
Febrile neutropenia			

subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Haemolysis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	0	0	3
Lymphopenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	4
Neutropenia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	5 / 35 (14.29%)
occurrences (all)	0	0	8
Thrombocytopenia			
subjects affected / exposed	1 / 11 (9.09%)	2 / 10 (20.00%)	8 / 35 (22.86%)
occurrences (all)	2	2	9
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Cataract nuclear			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Dry eye			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Lacrimation increased			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Vision blurred			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	0	1	2

Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Abdominal pain			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	1	0	3
Abdominal pain upper			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	6 / 35 (17.14%)
occurrences (all)	0	0	6
Anal fissure			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	4 / 35 (11.43%)
occurrences (all)	0	1	4
Dry mouth			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	3 / 35 (8.57%)
occurrences (all)	0	3	4
Diarrhoea			
subjects affected / exposed	1 / 11 (9.09%)	4 / 10 (40.00%)	6 / 35 (17.14%)
occurrences (all)	1	5	6
Dyspepsia			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	3 / 35 (8.57%)
occurrences (all)	0	2	3
Dysphagia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Flatulence			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	0	1	2
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Nausea			

subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	8 / 35 (22.86%)
occurrences (all)	1	1	10
Paraesthesia oral			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Vomiting			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	4 / 35 (11.43%)
occurrences (all)	0	0	6
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	1	1	0
Dermatitis atopic			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 11 (0.00%)	3 / 10 (30.00%)	3 / 35 (8.57%)
occurrences (all)	0	3	3
Nail ridging			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Rash			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Skin exfoliation			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Renal and urinary disorders			
Acute kidney injury			

subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	2 / 10 (20.00%) 2	3 / 35 (8.57%) 3
Haematuria subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	0 / 35 (0.00%) 0
Renal failure subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 10 (10.00%) 1	0 / 35 (0.00%) 0
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	1 / 10 (10.00%) 1	0 / 35 (0.00%) 0
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	1 / 35 (2.86%) 1
Hypothyroidism subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	2 / 11 (18.18%) 2	1 / 10 (10.00%) 1	3 / 35 (8.57%) 3
Back pain subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	2 / 35 (5.71%) 2
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	1 / 11 (9.09%) 1	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Muscle spasms subjects affected / exposed occurrences (all)	0 / 11 (0.00%) 0	0 / 10 (0.00%) 0	0 / 35 (0.00%) 0
Muscular weakness subjects affected / exposed occurrences (all)	3 / 11 (27.27%) 3	4 / 10 (40.00%) 4	5 / 35 (14.29%) 5
Neck pain			

subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Musculoskeletal pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	0	1	2
Osteonecrosis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Osteoporosis			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	2	0	0
Tendon pain			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Bronchitis			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	3 / 35 (8.57%)
occurrences (all)	0	1	3
COVID-19			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	4 / 35 (11.43%)
occurrences (all)	0	0	4
Conjunctivitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Cytomegalovirus viraemia			
subjects affected / exposed	2 / 11 (18.18%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	2	0	1
Cytomegalovirus infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	1	0	3



Cytomegalovirus infection reactivation			
subjects affected / exposed	2 / 11 (18.18%)	1 / 10 (10.00%)	3 / 35 (8.57%)
occurrences (all)	2	1	6
Device related infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Epstein-Barr virus infection reactivation			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	0	0	3
Hordeolum			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Herpes zoster			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Pneumonia viral			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Pneumonia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Parainfluenzae virus infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Paronychia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	1	0	0
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 11 (0.00%)	2 / 10 (20.00%)	0 / 35 (0.00%)
occurrences (all)	0	2	0
Respiratory tract infection			

subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	3 / 35 (8.57%)
occurrences (all)	0	0	3
Urinary tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	3
Upper respiratory tract infection			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	1 / 35 (2.86%)
occurrences (all)	0	1	1
Sinusitis			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Viral upper respiratory tract infection			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Urinary tract infection enterococcal			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	0 / 35 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	1	1	2
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	4 / 35 (11.43%)
occurrences (all)	0	0	4
Dehydration			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1
Fluid retention			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	0 / 35 (0.00%)
occurrences (all)	0	1	0
Hypercholesterolaemia			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1

Hyperglycaemia			
subjects affected / exposed	3 / 11 (27.27%)	0 / 10 (0.00%)	4 / 35 (11.43%)
occurrences (all)	3	0	4
Hyperkalaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	3
Hypertriglyceridaemia			
subjects affected / exposed	1 / 11 (9.09%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	1	1	2
Hypocalcaemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	4 / 35 (11.43%)
occurrences (all)	0	0	4
Hypomagnesaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	5 / 35 (14.29%)
occurrences (all)	0	1	9
Hyponatraemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	5 / 35 (14.29%)
occurrences (all)	0	1	8
Hypophosphataemia			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	2 / 35 (5.71%)
occurrences (all)	0	0	2
Hypokalaemia			
subjects affected / exposed	0 / 11 (0.00%)	1 / 10 (10.00%)	2 / 35 (5.71%)
occurrences (all)	0	1	2
Steroid diabetes			
subjects affected / exposed	0 / 11 (0.00%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	0	0	1
Vitamin D deficiency			
subjects affected / exposed	1 / 11 (9.09%)	0 / 10 (0.00%)	1 / 35 (2.86%)
occurrences (all)	1	0	1

<b>Non-serious adverse events</b>	Part 1 Expansion: itacitinib 400 mg QD + CS	Part 1 Expansion: itacitinib 300 mg BID + CS	Part 1 Expansion: Total
Total subjects affected by non-serious adverse events			
subjects affected / exposed	37 / 39 (94.87%)	27 / 29 (93.10%)	97 / 103 (94.17%)
Vascular disorders			

Deep vein thrombosis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Hot flush subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	3 / 29 (10.34%) 3	4 / 103 (3.88%) 4
Hypertension subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 8	9 / 29 (31.03%) 10	22 / 103 (21.36%) 24
Hypotension subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 29 (3.45%) 1	4 / 103 (3.88%) 4
Microangiopathy subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 2	2 / 29 (6.90%) 2	7 / 103 (6.80%) 9
Chest discomfort subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Fatigue subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 8	4 / 29 (13.79%) 4	17 / 103 (16.50%) 19
Influenza like illness subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	2 / 29 (6.90%) 5	2 / 103 (1.94%) 5
Oedema subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	2 / 29 (6.90%) 2	4 / 103 (3.88%) 4
Oedema peripheral subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 5	6 / 29 (20.69%) 7	17 / 103 (16.50%) 18
Pyrexia			

subjects affected / exposed occurrences (all)	5 / 39 (12.82%) 6	6 / 29 (20.69%) 6	15 / 103 (14.56%) 18
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Erectile dysfunction subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Vulvovaginal dryness subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 4	2 / 29 (6.90%) 2	6 / 103 (5.83%) 6
Dyspnoea subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	1 / 29 (3.45%) 1	8 / 103 (7.77%) 10
Epistaxis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	3 / 29 (10.34%) 5	5 / 103 (4.85%) 7
Nasal congestion subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Productive cough			

subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Pulmonary oedema subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	1 / 29 (3.45%) 1	4 / 103 (3.88%) 4
Confusional state subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Insomnia subjects affected / exposed occurrences (all)	8 / 39 (20.51%) 8	4 / 29 (13.79%) 5	15 / 103 (14.56%) 16
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	6 / 39 (15.38%) 14	6 / 29 (20.69%) 10	17 / 103 (16.50%) 31
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 6	2 / 29 (6.90%) 4	9 / 103 (8.74%) 15
Blood phosphorus decreased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	1 / 29 (3.45%) 1	3 / 103 (2.91%) 3
Blood bilirubin increased subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	1 / 29 (3.45%) 1	4 / 103 (3.88%) 4
Blood cholesterol increased			

subjects affected / exposed	4 / 39 (10.26%)	4 / 29 (13.79%)	11 / 103 (10.68%)
occurrences (all)	5	4	12
Blood creatinine increased			
subjects affected / exposed	4 / 39 (10.26%)	3 / 29 (10.34%)	10 / 103 (9.71%)
occurrences (all)	7	5	15
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	3 / 103 (2.91%)
occurrences (all)	1	1	3
Blood potassium decreased			
subjects affected / exposed	0 / 39 (0.00%)	2 / 29 (6.90%)	2 / 103 (1.94%)
occurrences (all)	0	2	2
Blood potassium increased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Blood sodium decreased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Blood triglycerides increased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Cytomegalovirus test positive			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	1	0	1
Drug level increased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	4 / 39 (10.26%)	1 / 29 (3.45%)	6 / 103 (5.83%)
occurrences (all)	6	2	9
Haemoglobin decreased			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	0	0	3
Haemoglobin increased			

subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Liver function test increased subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Lymphocyte count decreased subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 3	1 / 29 (3.45%) 1	3 / 103 (2.91%) 4
Neutrophil count decreased subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 5	0 / 29 (0.00%) 0	4 / 103 (3.88%) 5
Platelet count decreased subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 7	9 / 29 (31.03%) 11	22 / 103 (21.36%) 24
Weight increased subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	1 / 29 (3.45%) 1	4 / 103 (3.88%) 4
Fall subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 2	2 / 29 (6.90%) 2	4 / 103 (3.88%) 7
Limb injury subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Cardiac disorders			



Atrial fibrillation			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	5 / 103 (4.85%)
occurrences (all)	2	0	5
Bradycardia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Cardiac failure			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	6 / 103 (5.83%)
occurrences (all)	1	1	7
Nervous system disorders			
Balance disorder			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	2 / 39 (5.13%)	2 / 29 (6.90%)	7 / 103 (6.80%)
occurrences (all)	2	2	7
Dysgeusia			
subjects affected / exposed	3 / 39 (7.69%)	0 / 29 (0.00%)	5 / 103 (4.85%)
occurrences (all)	3	0	5
Headache			
subjects affected / exposed	6 / 39 (15.38%)	1 / 29 (3.45%)	9 / 103 (8.74%)
occurrences (all)	6	1	9
Hypoaesthesia			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	2	0	2
Neuropathy peripheral			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	0	0	2
Paraesthesia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	0	0	2
Sciatica			

subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Presyncope subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	0 / 103 (0.00%) 0
Polyneuropathy subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 2
Tremor subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	2 / 29 (6.90%) 2	4 / 103 (3.88%) 4
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	9 / 39 (23.08%) 13	10 / 29 (34.48%) 12	33 / 103 (32.04%) 43
Febrile neutropenia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 29 (3.45%) 1	1 / 103 (0.97%) 1
Haemolysis subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Leukopenia subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Lymphopenia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	3 / 103 (2.91%) 5
Neutropenia subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 11	3 / 29 (10.34%) 6	11 / 103 (10.68%) 25
Thrombocytopenia subjects affected / exposed occurrences (all)	7 / 39 (17.95%) 8	5 / 29 (17.24%) 5	20 / 103 (19.42%) 22
Eye disorders			
Blepharitis			

subjects affected / exposed	0 / 39 (0.00%)	2 / 29 (6.90%)	2 / 103 (1.94%)
occurrences (all)	0	2	2
Cataract			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Cataract nuclear			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Dry eye			
subjects affected / exposed	3 / 39 (7.69%)	2 / 29 (6.90%)	6 / 103 (5.83%)
occurrences (all)	4	2	7
Lacrimation increased			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences (all)	0	1	1
Vision blurred			
subjects affected / exposed	2 / 39 (5.13%)	2 / 29 (6.90%)	6 / 103 (5.83%)
occurrences (all)	2	2	6
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 39 (2.56%)	2 / 29 (6.90%)	5 / 103 (4.85%)
occurrences (all)	1	2	5
Abdominal pain			
subjects affected / exposed	3 / 39 (7.69%)	1 / 29 (3.45%)	7 / 103 (6.80%)
occurrences (all)	3	2	8
Abdominal pain upper			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	7 / 103 (6.80%)
occurrences (all)	0	1	7
Anal fissure			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	7 / 39 (17.95%)	2 / 29 (6.90%)	13 / 103 (12.62%)
occurrences (all)	7	2	13
Dry mouth			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	4 / 103 (3.88%)
occurrences (all)	1	0	5

Diarrhoea			
subjects affected / exposed	4 / 39 (10.26%)	6 / 29 (20.69%)	16 / 103 (15.53%)
occurrences (all)	6	9	21
Dyspepsia			
subjects affected / exposed	1 / 39 (2.56%)	2 / 29 (6.90%)	6 / 103 (5.83%)
occurrences (all)	2	2	7
Dysphagia			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	2	0	3
Flatulence			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	1	0	3
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	5 / 39 (12.82%)	2 / 29 (6.90%)	15 / 103 (14.56%)
occurrences (all)	6	2	18
Paraesthesia oral			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	5 / 103 (4.85%)
occurrences (all)	2	0	8
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	2	0	2
Dermatitis atopic			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Dry skin			

subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	5 / 103 (4.85%) 5
Nail ridging subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Pruritus subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	1 / 29 (3.45%) 1	3 / 103 (2.91%) 3
Rash subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	0 / 29 (0.00%) 0	4 / 103 (3.88%) 5
Skin exfoliation subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	0 / 29 (0.00%) 0	1 / 103 (0.97%) 1
Renal and urinary disorders Acute kidney injury subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 29 (3.45%) 1	4 / 103 (3.88%) 4
Haematuria subjects affected / exposed occurrences (all)	3 / 39 (7.69%) 4	0 / 29 (0.00%) 0	3 / 103 (2.91%) 4
Renal failure subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	1 / 29 (3.45%) 2	2 / 103 (1.94%) 3
Urinary incontinence subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	1 / 29 (3.45%) 1	1 / 103 (0.97%) 1
Endocrine disorders Cushingoid subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	3 / 103 (2.91%) 3
Hypothyroidism subjects affected / exposed occurrences (all)	2 / 39 (5.13%) 2	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	3 / 39 (7.69%)	3 / 29 (10.34%)	9 / 103 (8.74%)
occurrences (all)	4	4	11
Back pain			
subjects affected / exposed	3 / 39 (7.69%)	2 / 29 (6.90%)	7 / 103 (6.80%)
occurrences (all)	3	2	7
Musculoskeletal chest pain			
subjects affected / exposed	3 / 39 (7.69%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	3	0	3
Muscle spasms			
subjects affected / exposed	2 / 39 (5.13%)	4 / 29 (13.79%)	6 / 103 (5.83%)
occurrences (all)	2	4	6
Muscular weakness			
subjects affected / exposed	4 / 39 (10.26%)	0 / 29 (0.00%)	9 / 103 (8.74%)
occurrences (all)	4	0	9
Neck pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	0	0	2
Osteonecrosis			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	1 / 103 (0.97%)
occurrences (all)	0	1	1
Osteoporosis			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	2	0	2
Pain in extremity			
subjects affected / exposed	1 / 39 (2.56%)	2 / 29 (6.90%)	3 / 103 (2.91%)
occurrences (all)	2	2	4
Tendon pain			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Infections and infestations			
Bronchiolitis			

subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Bronchitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	0	0	3
COVID-19			
subjects affected / exposed	6 / 39 (15.38%)	4 / 29 (13.79%)	14 / 103 (13.59%)
occurrences (all)	6	4	14
Conjunctivitis			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Cytomegalovirus viraemia			
subjects affected / exposed	5 / 39 (12.82%)	3 / 29 (10.34%)	9 / 103 (8.74%)
occurrences (all)	5	4	10
Cytomegalovirus infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	3 / 103 (2.91%)
occurrences (all)	0	1	4
Cytomegalovirus infection reactivation			
subjects affected / exposed	8 / 39 (20.51%)	4 / 29 (13.79%)	15 / 103 (14.56%)
occurrences (all)	14	5	25
Device related infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	0	0	2
Epstein-Barr virus infection reactivation			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	4 / 103 (3.88%)
occurrences (all)	3	0	6
Hordeolum			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	2	0	2
Oral candidiasis			

subjects affected / exposed	2 / 39 (5.13%)	1 / 29 (3.45%)	3 / 103 (2.91%)
occurrences (all)	3	1	4
Pneumonia viral			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	3 / 39 (7.69%)	1 / 29 (3.45%)	5 / 103 (4.85%)
occurrences (all)	3	1	5
Parainfluenzae virus infection			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	1	0	1
Paronychia			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Respiratory syncytial virus infection			
subjects affected / exposed	2 / 39 (5.13%)	0 / 29 (0.00%)	2 / 103 (1.94%)
occurrences (all)	2	0	2
Respiratory tract infection			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	4 / 103 (3.88%)
occurrences (all)	0	2	5
Urinary tract infection			
subjects affected / exposed	3 / 39 (7.69%)	1 / 29 (3.45%)	5 / 103 (4.85%)
occurrences (all)	3	1	7
Upper respiratory tract infection			
subjects affected / exposed	0 / 39 (0.00%)	2 / 29 (6.90%)	2 / 103 (1.94%)
occurrences (all)	0	2	2
Skin infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Sinusitis			
subjects affected / exposed	1 / 39 (2.56%)	1 / 29 (3.45%)	4 / 103 (3.88%)
occurrences (all)	1	1	4
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	1 / 103 (0.97%)
occurrences (all)	0	0	1
Urinary tract infection enterococcal			



subjects affected / exposed	2 / 39 (5.13%)	1 / 29 (3.45%)	3 / 103 (2.91%)
occurrences (all)	2	1	3
Urinary tract infection bacterial			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	2	0	4
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	5 / 103 (4.85%)
occurrences (all)	1	0	5
Dehydration			
subjects affected / exposed	0 / 39 (0.00%)	1 / 29 (3.45%)	2 / 103 (1.94%)
occurrences (all)	0	1	2
Fluid retention			
subjects affected / exposed	0 / 39 (0.00%)	0 / 29 (0.00%)	0 / 103 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	3 / 39 (7.69%)	1 / 29 (3.45%)	5 / 103 (4.85%)
occurrences (all)	3	1	5
Hyperglycaemia			
subjects affected / exposed	5 / 39 (12.82%)	4 / 29 (13.79%)	13 / 103 (12.62%)
occurrences (all)	5	5	14
Hyperkalaemia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	3 / 103 (2.91%)
occurrences (all)	2	0	5
Hypertriglyceridaemia			
subjects affected / exposed	8 / 39 (20.51%)	3 / 29 (10.34%)	13 / 103 (12.62%)
occurrences (all)	9	3	14
Hypocalcaemia			
subjects affected / exposed	1 / 39 (2.56%)	0 / 29 (0.00%)	5 / 103 (4.85%)
occurrences (all)	3	0	7
Hypomagnesaemia			
subjects affected / exposed	2 / 39 (5.13%)	1 / 29 (3.45%)	8 / 103 (7.77%)
occurrences (all)	6	3	18
Hyponatraemia			
subjects affected / exposed	3 / 39 (7.69%)	3 / 29 (10.34%)	11 / 103 (10.68%)
occurrences (all)	5	4	17

Hypophosphataemia subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 3	2 / 29 (6.90%) 2	5 / 103 (4.85%) 7
Hypokalaemia subjects affected / exposed occurrences (all)	4 / 39 (10.26%) 6	6 / 29 (20.69%) 8	12 / 103 (11.65%) 16
Steroid diabetes subjects affected / exposed occurrences (all)	0 / 39 (0.00%) 0	2 / 29 (6.90%) 2	3 / 103 (2.91%) 3
Vitamin D deficiency subjects affected / exposed occurrences (all)	1 / 39 (2.56%) 1	0 / 29 (0.00%) 0	2 / 103 (1.94%) 2

<b>Non-serious adverse events</b>	Part 1 Expansion: CS monotherapy		
Total subjects affected by non-serious adverse events subjects affected / exposed	31 / 36 (86.11%)		
Vascular disorders			
Deep vein thrombosis subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Hot flush subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Hypertension subjects affected / exposed occurrences (all)	7 / 36 (19.44%) 7		
Hypotension subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Microangiopathy subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		

Chest discomfort subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Fatigue subjects affected / exposed occurrences (all)	5 / 36 (13.89%) 5		
Influenza like illness subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Oedema subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Oedema peripheral subjects affected / exposed occurrences (all)	6 / 36 (16.67%) 6		
Pyrexia subjects affected / exposed occurrences (all)	3 / 36 (8.33%) 4		
Immune system disorders Seasonal allergy subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Reproductive system and breast disorders Breast pain subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Erectile dysfunction subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Vulvovaginal dryness subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Respiratory, thoracic and mediastinal disorders			

Cough			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	4		
Dyspnoea			
subjects affected / exposed	5 / 36 (13.89%)		
occurrences (all)	5		
Epistaxis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Oropharyngeal pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Pulmonary oedema			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Anxiety			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Confusional state			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Depression			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Insomnia			
subjects affected / exposed	5 / 36 (13.89%)		
occurrences (all)	5		
Investigations			

Alanine aminotransferase increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Blood phosphorus decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Blood cholesterol increased			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	2		
Blood creatinine increased			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood potassium decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood potassium increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood sodium decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood triglycerides increased			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Cytomegalovirus test positive			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Drug level increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Haemoglobin decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Haemoglobin increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Liver function test increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Lymphocyte count decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Platelet count decreased			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Weight increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			

Contusion			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Limb injury			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Tooth fracture			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Wound			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cardiac disorders			
Atrial fibrillation			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Bradycardia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cardiac failure			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Nervous system disorders			
Balance disorder			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Dysgeusia			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Headache			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	4		
Hypoaesthesia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Paraesthesia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Sciatica			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Presyncope			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Polyneuropathy			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Tremor			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Febrile neutropenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Haemolysis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		



Leukopenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Lymphopenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Thrombocytopenia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cataract nuclear			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Dry eye			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Lacrimation increased			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal distension			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Abdominal pain			

subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Abdominal pain upper			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Anal fissure			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Dry mouth			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	5 / 36 (13.89%)		
occurrences (all)	5		
Dyspepsia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Dysphagia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Nausea			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Paraesthesia oral			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Vomiting			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Dermatitis atopic			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Dermatitis contact			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Dry skin			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Nail ridging			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Rash			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Skin exfoliation			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Renal failure			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Urinary incontinence			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Endocrine disorders			
Cushingoid			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Hypothyroidism			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Back pain			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Musculoskeletal chest pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Muscular weakness			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Neck pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Osteonecrosis			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Osteoporosis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Tendon pain			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Infections and infestations			
Bronchiolitis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
COVID-19			
subjects affected / exposed	5 / 36 (13.89%)		
occurrences (all)	5		
Conjunctivitis			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Cytomegalovirus viraemia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cytomegalovirus infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Cytomegalovirus infection reactivation			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	6		
Device related infection			

subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Epstein-Barr virus infection reactivation			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hordeolum			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Herpes zoster			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Oral candidiasis			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Pneumonia viral			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Parainfluenzae virus infection			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Paronychia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Respiratory syncytial virus infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Urinary tract infection			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		

Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Skin infection subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Sinusitis subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Viral upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Urinary tract infection enterococcal subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Dehydration subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Fluid retention subjects affected / exposed occurrences (all)	0 / 36 (0.00%) 0		
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 36 (2.78%) 1		
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 36 (5.56%) 2		
Hyperkalaemia			

subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	3 / 36 (8.33%)		
occurrences (all)	3		
Hypocalcaemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hypomagnesaemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hyponatraemia			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Hypophosphataemia			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		
Hypokalaemia			
subjects affected / exposed	2 / 36 (5.56%)		
occurrences (all)	2		
Steroid diabetes			
subjects affected / exposed	1 / 36 (2.78%)		
occurrences (all)	1		
Vitamin D deficiency			
subjects affected / exposed	0 / 36 (0.00%)		
occurrences (all)	0		



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
16 August 2018	The primary purpose of this amendment was to respond to Regulatory Authority feedback.
02 November 2018	The primary purpose of this amendment was to respond to Voluntary Harmonisation Procedure (VHP).
30 November 2018	The primary purpose of this amendment was to respond to VHP.
07 June 2019	The primary purpose of this amendment was to update and clarify exclusion criteria, the definition for treatment failure, dose-limiting toxicity (DLT) criteria, treatment of overdose, and maximum duration of study treatment, as well as to respond to health authorities.
30 August 2019	The primary purpose of this amendment was to ensure consistency between sections of the Protocol describing the reasons for discontinuation in response to VHP request.
16 December 2019	The primary purpose of this amendment was to specify the dose for Part 2 based on the analysis of data from Part 1 of the study, to update the dose modification and interruption guidelines, and to provide clarification in several areas of the Protocol.
03 April 2020	The primary purpose of this amendment was for the addition of a Part 1 Expansion part of the study and to update inclusion criteria, dose reduction scheme for concomitant medications, and itacitinib taper.
30 September 2021	The primary purpose of this amendment was for the discontinuation of Treatment Group C in the Part 1 Expansion part of the study and to update risk/benefit information, the dose reduction scheme for concomitant medications, and the frequency of pulmonary function tests in graft-versus-host disease (GVHD) follow-up.

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Based on Part 1 expansion preliminary efficacy data, Part 2 did not enroll participants. Part 1 Expansion participants who were tolerating and continuing to receive benefit from itacitinib could continue itacitinib treatment in study INCB 39110-801.

Notes: